描述

Drug delivery technologies play an increasingly important role in the drug-development process as a means to improve the efficacy of a drug, make a drug safer, more effective, or convenient, extend its patent life, or differentiate it in the marketplace. The global advanced drug delivery systems market in terms of revenue is set to grow by US$ 74 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 5.1% 在预测期内, 据数据和分析公司 StrategyHelix 称. Growth in the geriatric population, increasing prevalence of chronic diseases, increase in average income, rising demand for healthcare, rising demand for effective drug delivery design are the key factors driving market growth.

该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for advanced drug delivery systems. The global advanced drug delivery systems market is segmented on the basis of type, drug delivery carrier, 应用, 和地区. 按类型, it is categorized into oral drug delivery, injection-based drug delivery, inhalation/pulmonary drug delivery, transdermal drug delivery, transmucosal drug delivery, 和别的. The oral drug delivery segment held the largest market share in 2020. By drug delivery carrier, the advanced drug delivery systems market is divided into nanoparticles, monoclonal antibodies, liposomes, prodrugs, microparticles, dendrimer, 和别的. The nanoparticles segment accounted for the largest market share in 2020. Based on application, the advanced drug delivery systems market is divided into cardiovascular, central nervous system (CNS), 糖尿病, inflammatory & 过敏, oncology, ophthalmic, respiratory, urology, 和别的.

The report has profiled some of the key players of the market such as Abbott Laboratories, Amgen Inc., AstraZeneca plc, Baxter International Inc., Bayer HealthCare Pharmaceuticals Inc., Boston Scientific Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd..

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the advanced drug delivery systems market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

类型: oral drug delivery, injection-based drug delivery, inhalation/pulmonary drug delivery, transdermal drug delivery, transmucosal drug delivery, 和别的
Drug delivery carrier: nanoparticles, monoclonal antibodies, liposomes, prodrugs, microparticles, dendrimer, 和别的
应用: cardiovascular, central nervous system (CNS), 糖尿病, inflammatory & 过敏, oncology, ophthalmic, respiratory, urology, 和别的
地区: 北美, 亚太地区, 欧洲, 和世界其他地区 (排)
考虑年数: 本报告涵盖期间 2017 到 2027

利益相关者的主要好处

Get a comprehensive picture of the global advanced drug delivery systems market
根据当地数据和分析确定区域战略和战略重点
精准定位增长领域和投资趋势
Understand what the future of the global advanced drug delivery systems market looks like
确定竞争格局和机会之窗

目录

1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Advanced Drug Delivery Systems Market by Type
4.1 Oral Drug Delivery
4.2 Injection-Based Drug Delivery
4.3 Inhalation/Pulmonary Drug Delivery
4.4 Transdermal Drug Delivery
4.5 Transmucosal Drug Delivery
4.6 其他的
5. Advanced Drug Delivery Systems Market by Drug Delivery Carrier
5.1 Nanoparticles
5.2 Monoclonal Antibodies
5.3 Liposomes
5.4 Prodrugs
5.5 Microparticles
5.6 Dendrimer
5.7 其他的
6. Advanced Drug Delivery Systems Market by Application
6.1 Cardiovascular
6.2 Central Nervous System (Cns)
6.3 Diabetes
6.4 Inflammatory & Allergies
6.5 Oncology
6.6 Ophthalmic
6.7 Respiratory
6.8 Urology
6.9 其他的
7. Advanced Drug Delivery Systems Market by Region
7.1 北美
7.2 亚太地区
7.3 欧洲
7.4 世界其他地区 (排)
8. 公司简介
8.1 雅培实验室
8.2 Amgen Inc.
8.3 AstraZeneca plc
8.4 Baxter International Inc.
8.5 Bayer HealthCare Pharmaceuticals Inc.
8.6 Boston Scientific Corporation
8.7 F. Hoffmann-La Roche AG
8.8 葛兰素史克公司.
8.9 Merck KGaA
8.10 Novartis International AG
8.11 Pfizer Inc.
8.12 Sanofi SA
8.13 梯瓦制药工业有限公司.
9. 附录
9.1 关于StrategyHelix
9.2 免责声明